Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | President and COO | October 09, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 377,802 |
Ending reported balance
After 2026-10-13 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-10-09 · Exercise / conversion · Acquired 11,881 · Balance 389,683 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Row 2 · 2026-10-09 · Sale · Disposed 11,881 · Balance 377,802 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F2: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.99 to $26.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 3 · 2026-10-12 · Exercise / conversion · Acquired 11,881 · Balance 389,683 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Row 4 · 2026-10-12 · Sale · Disposed 9,181 · Balance 380,502 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F3: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.82 to $25.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 5 · 2026-10-12 · Sale · Disposed 2,700 · Balance 377,802 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F4: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.83 to $26.31, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 6 · 2026-10-13 · Exercise / conversion · Acquired 11,881 · Balance 389,683 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Row 7 · 2026-10-13 · Sale · Disposed 11,881 · Balance 377,802 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.10 to $25.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.14 · Expires 2032-03-04 | Direct | 296,610 |
Reported balance
After 2026-10-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-09 · Exercise / conversion · Disposed 11,881 · Balance 296,610 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6: The option is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.14 · Expires 2032-03-04 | Direct | 284,729 |
Reported balance
After 2026-10-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-10-12 · Exercise / conversion · Disposed 11,881 · Balance 284,729 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6: The option is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.14 · Expires 2032-03-04 | Direct | 272,848 |
Reported balance
After 2026-10-13 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-10-13 · Exercise / conversion · Disposed 11,881 · Balance 272,848 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6: The option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.99 to $26.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.82 to $25.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.83 to $26.31, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.10 to $25.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F6: The option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 20, 2026 Filed Apr 21, 2026 22:07 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001780664-26-000028 · form4.xml · derivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,326 Underlying: Common Stock · 14,722 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 22:07 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $14.55 | $277,323.00 |
DisclosureSEC source: 0001780664-26-000028 · form4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 399,484 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.14 to $14.82, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 22:07 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $8.46 | $124,548.12 |
DisclosureSEC source: 0001780664-26-000028 · form4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 418,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| April 17, 2026 Filed Apr 21, 2026 22:07 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001780664-26-000028 · form4.xml · derivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,048 Underlying: Common Stock · 14,722 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| April 17, 2026 Filed Apr 21, 2026 22:07 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $14.57 | $277,704.20 |
DisclosureSEC source: 0001780664-26-000028 · form4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 403,822 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.38 to $14.91, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 17, 2026 Filed Apr 21, 2026 22:07 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $8.46 | $124,548.12 |
DisclosureSEC source: 0001780664-26-000028 · form4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 422,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| April 16, 2026 Filed Apr 16, 2026 23:36 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001780664-26-000026 · form4.xml · derivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,770 Underlying: Common Stock · 14,722 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| April 16, 2026 Filed Apr 16, 2026 23:36 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $14.18 | $270,270.80 |
DisclosureSEC source: 0001780664-26-000026 · form4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 408,160 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.01 to $14.31, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 16, 2026 Filed Apr 16, 2026 23:36 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $8.46 | $124,548.12 |
DisclosureSEC source: 0001780664-26-000026 · form4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 427,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| April 15, 2026 Filed Apr 16, 2026 23:36 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001780664-26-000026 · form4.xml · derivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,492 Underlying: Common Stock · 14,722 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| April 15, 2026 Filed Apr 16, 2026 23:36 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $14.61 | $278,466.60 |
DisclosureSEC source: 0001780664-26-000026 · form4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 412,498 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.49 to $14.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 15, 2026 Filed Apr 16, 2026 23:36 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $8.46 | $124,548.12 |
DisclosureSEC source: 0001780664-26-000026 · form4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 431,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 23:36 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001780664-26-000026 · form4.xml · derivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,214 Underlying: Common Stock · 14,722 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 23:36 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $14.56 | $277,513.60 |
DisclosureSEC source: 0001780664-26-000026 · form4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 416,836 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.17 to $14.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 23:36 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $8.46 | $124,548.12 |
DisclosureSEC source: 0001780664-26-000026 · form4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 435,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| April 13, 2026 Filed Apr 13, 2026 23:44 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 6,613 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001780664-26-000024 · form4.xml · derivative · entry 14 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,936 Underlying: Common Stock · 6,613 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F9 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| April 13, 2026 Filed Apr 13, 2026 23:44 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 8,109 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001780664-26-000024 · form4.xml · derivative · entry 13 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,109 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 13, 2026 Filed Apr 13, 2026 23:44 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 3,338 | $14.08 | $46,999.04 |
DisclosureSEC source: 0001780664-26-000024 · form4.xml · nonDerivative · entry 10 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 421,174 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F7 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.87 to $14.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 13, 2026 Filed Apr 13, 2026 23:44 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 15,722 | $12.95 | $203,599.90 |
DisclosureSEC source: 0001780664-26-000024 · form4.xml · nonDerivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 424,512 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.83 to $13.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 13, 2026 Filed Apr 13, 2026 23:44 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 6,613 | $8.46 | $55,945.98 |
DisclosureSEC source: 0001780664-26-000024 · form4.xml · nonDerivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 440,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| April 13, 2026 Filed Apr 13, 2026 23:44 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 8,109 | $7.27 | $58,952.43 |
DisclosureSEC source: 0001780664-26-000024 · form4.xml · nonDerivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 433,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| April 10, 2026 Filed Apr 13, 2026 23:44 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001780664-26-000024 · form4.xml · derivative · entry 12 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,109 Underlying: Common Stock · 14,722 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 10, 2026 Filed Apr 13, 2026 23:44 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 400 | $13.48 | $5,392.00 |
DisclosureSEC source: 0001780664-26-000024 · form4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 425,512 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.44 to $13.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 10, 2026 Filed Apr 13, 2026 23:44 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 18,660 | $12.75 | $237,915.00 |
DisclosureSEC source: 0001780664-26-000024 · form4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 425,912 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.43 to $13.42, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 10, 2026 Filed Apr 13, 2026 23:44 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $7.27 | $107,028.94 |
DisclosureSEC source: 0001780664-26-000024 · form4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 444,572 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| April 09, 2026 Filed Apr 13, 2026 23:44 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001780664-26-000024 · form4.xml · derivative · entry 11 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,831 Underlying: Common Stock · 14,722 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 09, 2026 Filed Apr 13, 2026 23:44 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 2,100 | $14.44 | $30,324.00 |
DisclosureSEC source: 0001780664-26-000024 · form4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 429,850 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.40 to $14.62, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 09, 2026 Filed Apr 13, 2026 23:44 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 16,960 | $13.79 | $233,878.40 |
DisclosureSEC source: 0001780664-26-000024 · form4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 431,950 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.40 to $14.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 09, 2026 Filed Apr 13, 2026 23:44 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $7.27 | $107,028.94 |
DisclosureSEC source: 0001780664-26-000024 · form4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 448,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| April 08, 2026 Filed Apr 8, 2026 23:48 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 11,881 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780664-26-000022 · form4.xml · derivative · entry 12 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 391,658 Underlying: Common Stock · 11,881 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 08, 2026 Filed Apr 8, 2026 23:48 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001780664-26-000022 · form4.xml · derivative · entry 11 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,553 Underlying: Common Stock · 14,722 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 08, 2026 Filed Apr 8, 2026 23:48 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 100 | $15.48 | $1,548.00 |
DisclosureSEC source: 0001780664-26-000022 · form4.xml · nonDerivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 434,188 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| April 08, 2026 Filed Apr 8, 2026 23:48 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 30,841 | $14.83 | $457,372.03 |
DisclosureSEC source: 0001780664-26-000022 · form4.xml · nonDerivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 434,288 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.45 to $15.21, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 08, 2026 Filed Apr 8, 2026 23:48 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 11,881 | $12.14 | $144,235.34 |
DisclosureSEC source: 0001780664-26-000022 · form4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 465,129 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| April 08, 2026 Filed Apr 8, 2026 23:48 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $7.27 | $107,028.94 |
DisclosureSEC source: 0001780664-26-000022 · form4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 453,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 23:48 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001780664-26-000022 · form4.xml · derivative · entry 10 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,275 Underlying: Common Stock · 14,722 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 23:48 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $13.56 | $258,453.60 |
DisclosureSEC source: 0001780664-26-000022 · form4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 438,526 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.39 to $13.83, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 23:48 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $7.27 | $107,028.94 |
DisclosureSEC source: 0001780664-26-000022 · form4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 457,586 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 23:48 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001780664-26-000022 · form4.xml · derivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,997 Underlying: Common Stock · 14,722 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 23:48 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $14.33 | $273,129.80 |
DisclosureSEC source: 0001780664-26-000022 · form4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 442,864 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.05 to $14.86, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 23:48 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $7.27 | $107,028.94 |
DisclosureSEC source: 0001780664-26-000022 · form4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 461,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| April 02, 2026 Filed Apr 2, 2026 23:16 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001780664-26-000020 · form4.xml · derivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,719 Underlying: Common Stock · 14,722 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 02, 2026 Filed Apr 2, 2026 23:16 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $14.60 | $278,276.00 |
DisclosureSEC source: 0001780664-26-000020 · form4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 447,202 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 02, 2026 Filed Apr 2, 2026 23:16 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $7.27 | $107,028.94 |
DisclosureSEC source: 0001780664-26-000020 · form4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 23:16 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001780664-26-000020 · form4.xml · derivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,441 Underlying: Common Stock · 14,722 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 23:16 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $14.45 | $275,417.00 |
DisclosureSEC source: 0001780664-26-000020 · form4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 451,540 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.66, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 23:16 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $7.27 | $107,028.94 |
DisclosureSEC source: 0001780664-26-000020 · form4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 470,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 31, 2026 Filed Mar 31, 2026 22:56 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001780664-26-000018 · form4.xml · derivative · entry 10 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,163 Underlying: Common Stock · 14,722 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 31, 2026 Filed Mar 31, 2026 22:56 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $13.45 | $256,357.00 |
DisclosureSEC source: 0001780664-26-000018 · form4.xml · nonDerivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,878 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.10 to $13.87, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 31, 2026 Filed Mar 31, 2026 22:56 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $7.27 | $107,028.94 |
DisclosureSEC source: 0001780664-26-000018 · form4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 474,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.